Hyperglycemia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hyperglycemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hyperglycemia - Pipeline Review, H2 2014', provides an overview of the Hyperglycemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperglycemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hyperglycemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperglycemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperglycemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperglycemia Overview 6
Therapeutics Development 7
Pipeline Products for Hyperglycemia - Overview 7
Pipeline Products for Hyperglycemia - Comparative Analysis 8
Hyperglycemia - Therapeutics under Development by Companies 9
Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10
Hyperglycemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hyperglycemia - Products under Development by Companies 14
Hyperglycemia - Products under Investigation by Universities/Institutes 15
Hyperglycemia - Companies Involved in Therapeutics Development 16
Kissei Pharmaceutical Co., Ltd. 16
Mitsubishi Tanabe Pharma Corporation 17
PhaseBio Pharmaceuticals, Inc. 18
Hyperglycemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
PE-0139 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
KR-62980 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ZLN-005 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit PEPCK for Diabetes and Hyperglycemia - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
55-P-0251 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
FGH-10019 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Hyperglycemia - Recent Pipeline Updates 42
Hyperglycemia - Dormant Projects 43
Hyperglycemia - Product Development Milestones 44
Featured News & Press Releases 44
Dec 06, 2011: Study Shows Combination Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia In Type 1 And Type 2 Diabetes Patients 44
Nov 15, 2011: PhaseBio Announces Positive Results From Phase I/IIa Trial Of Glymera For Treatment Of Hyperglycemia In Patients With Type 2 Diabetes 44
Jul 21, 2011: Kissei Pharma Launches Glubes In Japan For Treatment Of Type 2 Diabetes 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Hyperglycemia, H2 2014 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Hyperglycemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 16
Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 17
Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Hyperglycemia Therapeutics - Recent Pipeline Updates, H2 2014 42
Hyperglycemia - Dormant Projects, H2 2014 43